Home » Boehringer Ingelheim’s Lung Cancer Drug Gets Fast-Track Status
Boehringer Ingelheim’s Lung Cancer Drug Gets Fast-Track Status
Boehringer Ingelheim’s investigational nonsmall cell lung cancer or NSCLC treatment BIBW 2992 has received fast track designation status from the FDA.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct